Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
REGULATORY
5 Wholesalers Ordered to Pay 627 Million Yen in Surcharge over Kyushu Bid-Rigging
Japan’s antitrust watchdog said on March 24 that it has ordered five pharmaceutical wholesalers to pay surcharges totaling 627 million yen over a bid-rigging scandal involving drug purchases made in Kyushu by a state-backed hospital system. The Japan Fair Trade…
To read the full story
Related Article
- JCHO Bars 6 Wholesalers from Drug Procurement Bids in Kyushu
March 30, 2023
- JOHAS Follows Suit to Suspend 6 Wholesalers from Future Bids
March 29, 2023
- Six Wholesalers Barred from NHO Bids after FTC Confirms Bid-Rigging
March 28, 2023
- 5 Wholesalers to Be Slapped with 600 Million Yen Surcharges over Kyushu Bid-Rigging Case
January 18, 2023
- 6 Wholesalers Raided over Suspected Bid-Rigging in Kyushu
November 10, 2021
REGULATORY
- Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
- 2024 Reform Spurred New Development Activity, 20 Projects Entered Clinic: Industry Poll
December 11, 2025
- Regenerative Medicine Group Accepts Deferred Debate on Market Expansion Re-Pricing
December 11, 2025
- Wholesalers Urge Price Hikes on Sub-20-Yen Drugs as Negative Margins Mount
December 11, 2025
- Two Bayer/AskBio Gene Therapies Bag Sakigake Designation
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…